resubmission of new drug application for iluvi, page-3

Alimera's Iluvien Gets a Second Chance

Alimera Sciences Inc., a biopharmaceutical company specializing in prescription ophthalmic pharmaceuticals, could see near-term upside after announcing plans to re-file for FDA approval of its Iluvien technology. After failing to initially approve the drug, the FDA wanted to see safety and efficacy data through month 36 of the Fame study and held a meeting with management to discuss the results.

Analysts like Oppenheimer see a high probability that Iluvien will be approved this time around and predict that the company's stock price will rise significantly following the approval. Notably, the company has also submitted applications for the drug device in the United Kingdom, Austria, France, Germany, Italy, Portugal and Spain that could unlock further value.

http://seekingalpha.com/article/268837-3-pharma-stocks-with-near-term-catalysts-and-potential